A Phase Ib, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2017
At a glance
- Drugs Cobimetinib (Primary) ; Pictrelisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genentech
- 04 Nov 2016 Status changed from completed to discontinued.
- 10 Jun 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
- 27 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.